1-5 of 5
John W. Marks
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Construction and Characterization of Novel, Completely Human Serine Protease Therapeutics Targeting Her2/neu

Free
Yu Cao, Khalid A. Mohamedali, John W. Marks, Lawrence H. Cheung, Walter N. Hittelman, Michael G. Rosenblum
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (6): 979–991.
https://doi.org/10.1158/1535-7163.MCT-13-0002
Published: 09 June 2013
View articletitled, Construction and Characterization of Novel, Completely Human Serine Protease Therapeutics Targeting Her2/neu
Open the PDF for Construction and Characterization of Novel, Completely Human Serine Protease Therapeutics Targeting Her2/neu in another window
Journal Articles

Single-Chain Antibody-Based Immunotoxins Targeting Her2/neu: Design Optimization and Impact of Affinity on Antitumor Efficacy and Off-Target Toxicity

Free
Yu Cao, James D. Marks, Qian Huang, Stephen I. Rudnick, Chiyi Xiong, Walter N. Hittelman, Xiaoxia Wen, John W. Marks, Lawrence H. Cheung, Kim Boland, Chun Li, Gregory P. Adams, Michael G. Rosenblum
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2012) 11 (1): 143–153.
https://doi.org/10.1158/1535-7163.MCT-11-0519
Published: 09 January 2012
View articletitled, Single-Chain Antibody-Based Immunotoxins Targeting Her2/neu: Design Optimization and Impact of Affinity on Antitumor Efficacy and Off-Target Toxicity
Open the PDF for Single-Chain Antibody-Based Immunotoxins Targeting Her2/neu: Design Optimization and Impact of Affinity on Antitumor Efficacy and Off-Target Toxicity in another window
Includes: Supplementary data
Journal Articles

Development and Characterization of a Potent Immunoconjugate Targeting the Fn14 Receptor on Solid Tumor Cells

Free
Hong Zhou, John W. Marks, Walter N. Hittelman, Hideo Yagita, Lawrence H. Cheung, Michael G. Rosenblum, Jeffrey A. Winkles
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (7): 1276–1288.
https://doi.org/10.1158/1535-7163.MCT-11-0161
Published: 06 July 2011
View articletitled, Development and Characterization of a Potent Immunoconjugate Targeting the Fn14 Receptor on Solid Tumor Cells
Open the PDF for Development and Characterization of a Potent Immunoconjugate Targeting the Fn14 Receptor on Solid Tumor Cells in another window
Journal Articles

The rGel/BLyS fusion toxin specifically targets malignant B cells expressing the BLyS receptors BAFF-R, TACI, and BCMA

Free
Mi-Ae Lyu, Lawrence H. Cheung, Walter N. Hittelman, John W. Marks, Ricardo C.T. Aguiar, Michael G. Rosenblum
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (2): 460–470.
https://doi.org/10.1158/1535-7163.MCT-06-0254
Published: 16 February 2007
View articletitled, The rGel/BLyS fusion toxin specifically targets malignant B cells expressing the BLyS receptors BAFF-R, TACI, and BCMA
Open the PDF for The rGel/BLyS fusion toxin specifically targets malignant B cells expressing the BLyS receptors BAFF-R, TACI, and BCMA in another window
Journal Articles

Retinoic acid-induced CD38 antigen as a target for immunotoxin-mediated killing of leukemia cells

Free
Kapil Mehta, Larry Ocanas, Fabio Malavasi, John W. Marks, Michael G. Rosenblum
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2004) 3 (3): 345–352.
https://doi.org/10.1158/1535-7163.345.3.3
Published: 16 March 2004
View articletitled, Retinoic acid-induced CD38 antigen as a target for immunotoxin-mediated killing of leukemia cells
Open the PDF for Retinoic acid-induced CD38 antigen as a target for immunotoxin-mediated killing of leukemia cells in another window